IGFBP2 and lung carcinoma: In this study, we also detected serum IGFBP-2 levels in 98 patients with lung cancer, 17 patients with benign lung disease, and 23 normal controls, and found that serum IGFBP-2 levels were significantly elevated in lung cancer patients (mean, 1,304.273 ng/ml; median, 1,225.109 ng/ml; range, 265–3,584.674 ng/ml) compared with controls (749.428, 777.228, 51.944–1,384.217 ng/ml) (P<0.0001, Fig. 3A).